Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 15/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058329 | 1.00 | ITK (0.51) | ITKDGAT2KDM4EHSD17B10GPR88 | |
| SCHEMBL18706738 | 0.80 | ITK (0.51) | ITKDGAT2KDM4EHSD17B10GPR88 | |
| SCHEMBL18706578 | 0.78 | ITK (0.47) | ITKDGAT2KDM4EHSD17B10GPR88 | |
| SCHEMBL20380102 | 0.78 | ALDH1A1 (0.52) | DGAT2ALDH1A1 | |
| SCHEMBL24543085 | 0.77 | GPR88 (0.46) | ITKDGAT2GPR88SLC6A4OPRK1 | |
| SCHEMBL29730103 | 0.76 | GPR88 (0.56) | ITKGPR88SLC6A4OPRK1NPC1 | |
| SCHEMBL24543201 | 0.76 | GPR88 (0.56) | ITKGPR88SLC6A4OPRK1NPC1 | |
| SCHEMBL29730320 | 0.76 | GPR88 (0.56) | ITKGPR88SLC6A4OPRK1NPC1 | |
| SCHEMBL15219719 | 0.75 | ITK (0.46) | ITKGPR88NPC1MAPTRAB9A | |
| SCHEMBL29295352 | 0.75 | ITK (0.46) | ITKGPR88NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2794563-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093842-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | ITK 3301/4885DGAT2 1513/4885KDM4E 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.